ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
Incident HCV infection more than doubled among HIV-positive MSM with no history of injection drug use between 1995 and 2023.
Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...
Scientists discovered genes in the tuberculosis bacterium that becomes essential for the pathogen's survival when it's exposed to air through coughing. These genes could be targets for new therapies ...
Tuberculosis lives and thrives in the lungs. When the bacteria that cause the disease are coughed into the air, they are ...
During his address to Congress on March 4, Donald Trump alleged that the Biden administration had spent $8 million "for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback